The effect of mucodentol on covid-19 symptoms
Phase 3
- Conditions
- COVID-19.
- Registration Number
- IRCT20200711048076N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
Age over 18 years.
Mental and physical ability to use this drug for three weeks.
Lack of sensitivity to similar drugs.
Existence of a person with COVID -19 in the family.
People are aware of time, place and person, are in a natural state mentally and mentally, Be able to communicate verbally for a telephone interview.
Exclusion Criteria
Covid-19 infection
Drug sensitivity
Underlying diseases: Cardiovascular diseases, Diabetes, Immune system deficiency,...
Pregnancy or lactation
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method